Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ortho Clinical Diagnostics Improves Oncology Testing Portfolio with Expanded PSA Offerings

Published: Tuesday, June 12, 2012
Last Updated: Tuesday, June 12, 2012
Bookmark and Share
VITROS® Total PSA Assay II and VITROS® Free PSA Assay receive CE Mark.

Ortho-Clinical Diagnostics, Inc. (OCD) announced CE Mark (Conformité Européenne) for the VITROS® Immunodiagnostic Products Total PSA II Assay and VITROS® Immunodiagnostic Products Free PSA Assay, two new diagnostic tests that aid in monitoring and detecting prostate cancer.
Prostate cancer occurs when a malignant tumor forms in the tissue of the prostate, a gland in the male reproductive system. According to the World Cancer Research Fund International, one in six men is estimated to develop prostate cancer in their lifetime. Early detection is crucial to ensuring better health outcomes for patients.
With the introduction of these fully-automated immunoassays, OCD now offers a fully updated, state-of-the-art oncology portfolio for the early detection of prostate cancer. The VITROS® Total PSA Assay II, a next-generation, prostate-specific antigen test, offers analytical sensitivity with a broad measuring range to help monitor and screen patients. The VITROS® Free PSA Assay, the newest addition to OCD’s VITROS® oncology menu, complements the VITROS® Total PSA II Assay to help clinicians better manage their patients. The two assays offer an extremely competitive time-to-first result of 24 minutes, and are approved for use on the VITROS® 5600 Integrated, VITROS® 3600 Immunodiagnostic and VITROS® ECi/ECiQ Immunodiagnostic Systems.
“The competitive performance of these two assays is extremely compelling and we found that the measurement range is better suited to the circumstances we face in our laboratory,” said Dr. Jeanne-Pierre Bouilloux, Director of Laboratory at LBM LXBio in South France. “I am pleased that OCD now offers these new tests with low range sensitivities, which are increasingly important for clinicians who have patients treated through hormone therapy or total resection surgery.”

The CE Marking secures OCD’s prostate cancer assay marketing rights in Europe and other markets that accept CE Marking.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Startup Seeks More Precise Prostate Cancer Screening
Gregor Diagnostics aims to bring a non-invasive prostate cancer screening test to the market.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos